Nexium Pay-For-Delay Trial Needs Redo, Buyers Tell 1st Circ.
Classes of direct buyers and end-payors of Nexium on Wednesday again pushed the First Circuit to grant a new trial after a district court rejected their claims that AstraZeneca's Hatch-Waxman Act...To view the full article, register now.
Already a subscriber? Click here to view full article